RU2011127051A - MEDICINAL PRODUCT FOR REDUCING RESISTANCE TO INSULIN AND FOR TREATING SUGAR DIABETES, METHOD FOR REDUCING RESISTANCE TO INSULIN, METHOD FOR TREATING SUGAR DIABETES AND METHOD FOR TREATING ISOMEPHELIUM IN SUCHEMIUM - Google Patents

MEDICINAL PRODUCT FOR REDUCING RESISTANCE TO INSULIN AND FOR TREATING SUGAR DIABETES, METHOD FOR REDUCING RESISTANCE TO INSULIN, METHOD FOR TREATING SUGAR DIABETES AND METHOD FOR TREATING ISOMEPHELIUM IN SUCHEMIUM Download PDF

Info

Publication number
RU2011127051A
RU2011127051A RU2011127051/15A RU2011127051A RU2011127051A RU 2011127051 A RU2011127051 A RU 2011127051A RU 2011127051/15 A RU2011127051/15 A RU 2011127051/15A RU 2011127051 A RU2011127051 A RU 2011127051A RU 2011127051 A RU2011127051 A RU 2011127051A
Authority
RU
Russia
Prior art keywords
antibodies
activated
potentiated
synthase
endothelial
Prior art date
Application number
RU2011127051/15A
Other languages
Russian (ru)
Other versions
RU2509572C2 (en
Inventor
Олег Ильич Эпштейн
Original Assignee
Олег Ильич Эпштейн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олег Ильич Эпштейн filed Critical Олег Ильич Эпштейн
Priority to RU2011127051/15A priority Critical patent/RU2509572C2/en
Priority to CN2011800454899A priority patent/CN103118707A/en
Priority to MX2013000543A priority patent/MX2013000543A/en
Priority to MYPI2013000225A priority patent/MY160979A/en
Priority to CZ20130124A priority patent/CZ2013124A3/en
Priority to ES201390009A priority patent/ES2445846R1/en
Priority to EA201300124A priority patent/EA029847B1/en
Priority to PE2013000076A priority patent/PE20130398A1/en
Priority to GB1302924.4A priority patent/GB2496799B/en
Priority to PCT/IB2011/002350 priority patent/WO2012007845A2/en
Priority to KR1020187032943A priority patent/KR20180127515A/en
Priority to SG2013002324A priority patent/SG187038A1/en
Priority to EP11775838.3A priority patent/EP2593140A2/en
Priority to CA2804966A priority patent/CA2804966A1/en
Priority to PCT/IB2011/002177 priority patent/WO2012010966A2/en
Priority to DE112011102358T priority patent/DE112011102358T5/en
Priority to SG2013004817A priority patent/SG187578A1/en
Priority to ES201390006A priority patent/ES2440393R1/en
Priority to IT000627A priority patent/ITTO20110627A1/en
Priority to EA201300126A priority patent/EA030566B1/en
Priority to EP11773314.7A priority patent/EP2595658A2/en
Priority to BR112013001299A priority patent/BR112013001299A2/en
Priority to BR112013000840A priority patent/BR112013000840A2/en
Priority to KR1020137004330A priority patent/KR20130103486A/en
Priority to FR1156480A priority patent/FR2962913A1/en
Priority to IT000639A priority patent/ITTO20110639A1/en
Priority to CZ20130105A priority patent/CZ2013105A3/en
Priority to NZ606964A priority patent/NZ606964A/en
Priority to AU2011278038A priority patent/AU2011278038B2/en
Priority to DE112011102396T priority patent/DE112011102396T5/en
Priority to JP2013519175A priority patent/JP2013538186A/en
Priority to KR1020137003861A priority patent/KR20140014059A/en
Priority to EEP201300007A priority patent/EE05761B1/en
Priority to EEP201300006A priority patent/EE201300006A/en
Priority to JP2013520235A priority patent/JP2013533268A/en
Priority to NZ606767A priority patent/NZ606767A/en
Priority to FR1156482A priority patent/FR2962656A1/en
Priority to AU2011281240A priority patent/AU2011281240B2/en
Priority to EP19213849.3A priority patent/EP3693018A1/en
Priority to SG10201505561TA priority patent/SG10201505561TA/en
Priority to CA2805961A priority patent/CA2805961A1/en
Priority to GB1302649.7A priority patent/GB2495884B/en
Priority to US13/135,901 priority patent/US9308275B2/en
Priority to US13/135,891 priority patent/US8617555B2/en
Priority to SE1350212A priority patent/SE1350212A1/en
Priority to PE2013000114A priority patent/PE20130815A1/en
Priority to MX2013000804A priority patent/MX2013000804A/en
Priority to GB1707872.6A priority patent/GB2552405B/en
Priority to ARP110102578A priority patent/AR082247A1/en
Priority to ARP110102642A priority patent/AR082312A1/en
Priority to CL2013000099A priority patent/CL2013000099A1/en
Publication of RU2011127051A publication Critical patent/RU2011127051A/en
Priority to CL2013000200A priority patent/CL2013000200A1/en
Priority to NO20130222A priority patent/NO20130222A1/en
Priority to DKPA201370079A priority patent/DK201370079A/en
Priority to LT2013016A priority patent/LT5988B/en
Priority to FI20135143A priority patent/FI20135143L/en
Priority to NO20130265A priority patent/NO20130265A1/en
Priority to LT2013018A priority patent/LT5980B/en
Priority to DKPA201370089A priority patent/DK201370089A/en
Priority to FI20135152A priority patent/FI20135152L/en
Application granted granted Critical
Publication of RU2509572C2 publication Critical patent/RU2509572C2/en
Priority to US15/060,202 priority patent/US20160251448A1/en
Priority to US15/060,157 priority patent/US20160244531A1/en
Priority to JP2016131729A priority patent/JP2016222684A/en
Priority to JP2016135750A priority patent/JP2016216483A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

1. Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, содержащее активированную - потенцированную форму антител к рецептору инсулина, отличающееся тем, что выполнено в виде фармацевтической композиции и включает в качестве дополнительного - усиливающего компонента активированную - потенцированную форму антител к эндотелиальной NO-синтазе.2. Лекарственное средство по п.1, отличающееся тем, что содержит активированную - потенцированную форму антител к С-концевому фрагменту β-субъединицы рецептора инсулина и активированную - потенцированную форму антител к эндотелиальной NO-синтазе.3. Лекарственное средство по п.1 или 2, отличающееся тем, что активированную - потенцированную форму антител к С-концевому фрагменту β-субъединицы рецептора инсулина и активированную - потенцированную форму антител к эндотелиальной NO-синтазе используют в виде активированного - потенцированного водного или водно-спиртового раствора, активность которого обусловлена процессом многократного разведения матричного раствора соответствующих антител в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - многократным встряхиванием каждого разведения.4. Лекарственное средство по п.1 или 2, отличающееся тем, что фармацевтическая композиция выполнена в твердой лекарственной форме и содержит эффективное количество гранул нейтрального носителя, насыщенного смесью активированной - потенцированной формой антител к С-концевому фрагменту β-субъединицы рецептора инсулина и активированную - потенцированную форму антител к эндотелиальной NO-синтазе, и фармацевт�1. A drug for reducing insulin resistance and for the treatment of diabetes mellitus, containing an activated - potentiated form of antibodies to the insulin receptor, characterized in that it is made in the form of a pharmaceutical composition and includes, as an additional - enhancing component, an activated - potentiated form of antibodies to endothelial NO -synthase. 2. A medicinal product according to claim 1, characterized in that it contains an activated - potentiated form of antibodies to the C-terminal fragment of the β-subunit of the insulin receptor and an activated - potentiated form of antibodies to endothelial NO-synthase. The drug according to claim 1 or 2, characterized in that the activated - potentiated form of antibodies to the C-terminal fragment of the β-subunit of the insulin receptor and the activated - potentiated form of antibodies to endothelial NO-synthase are used in the form of an activated - potentiated aqueous or aqueous-alcoholic solution, the activity of which is due to the process of multiple dilution of the matrix solution of the corresponding antibodies in an aqueous or aqueous-alcoholic solvent in combination with external mechanical action - repeated shaking of each dilution. 4. A medicinal product according to claim 1 or 2, characterized in that the pharmaceutical composition is made in a solid dosage form and contains an effective amount of neutral carrier granules saturated with a mixture of an activated - potentiated form of antibodies to the C-terminal fragment of the β-subunit of the insulin receptor and an activated - potentiated form antibodies to endothelial NO synthase, and pharmacist

Claims (20)

1. Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, содержащее активированную - потенцированную форму антител к рецептору инсулина, отличающееся тем, что выполнено в виде фармацевтической композиции и включает в качестве дополнительного - усиливающего компонента активированную - потенцированную форму антител к эндотелиальной NO-синтазе.1. A medicine for reducing insulin resistance and for the treatment of diabetes mellitus, containing an activated - potentiated form of antibodies to an insulin receptor, characterized in that it is made in the form of a pharmaceutical composition and includes an activated - potentiated form of antibodies to endothelial NO as an additional reinforcing component synthase. 2. Лекарственное средство по п.1, отличающееся тем, что содержит активированную - потенцированную форму антител к С-концевому фрагменту β-субъединицы рецептора инсулина и активированную - потенцированную форму антител к эндотелиальной NO-синтазе.2. The drug according to claim 1, characterized in that it contains an activated - potentiated form of antibodies to the C-terminal fragment of the β-subunit of the insulin receptor and an activated - potentiated form of antibodies to endothelial NO synthase. 3. Лекарственное средство по п.1 или 2, отличающееся тем, что активированную - потенцированную форму антител к С-концевому фрагменту β-субъединицы рецептора инсулина и активированную - потенцированную форму антител к эндотелиальной NO-синтазе используют в виде активированного - потенцированного водного или водно-спиртового раствора, активность которого обусловлена процессом многократного разведения матричного раствора соответствующих антител в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - многократным встряхиванием каждого разведения.3. The drug according to claim 1 or 2, characterized in that the activated - potentiated form of antibodies to the C-terminal fragment of the β-subunit of the insulin receptor and the activated - potentiated form of antibodies to endothelial NO synthase are used in the form of an activated - potentiated aqueous or aqueous -alcohol solution, the activity of which is due to the process of repeated dilution of the matrix solution of the corresponding antibodies in an aqueous or aqueous-alcohol solvent in combination with external mechanical stress - many gokratnym shaking each dilution. 4. Лекарственное средство по п.1 или 2, отличающееся тем, что фармацевтическая композиция выполнена в твердой лекарственной форме и содержит эффективное количество гранул нейтрального носителя, насыщенного смесью активированной - потенцированной формой антител к С-концевому фрагменту β-субъединицы рецептора инсулина и активированную - потенцированную форму антител к эндотелиальной NO-синтазе, и фармацевтически приемлемые добавки.4. The drug according to claim 1 or 2, characterized in that the pharmaceutical composition is made in solid dosage form and contains an effective amount of granules of a neutral carrier saturated with a mixture of an activated - potentiated form of antibodies to the C-terminal fragment of the insulin receptor β-subunit and activated - potentiated form of antibodies to endothelial NO synthase; and pharmaceutically acceptable additives. 5. Лекарственное средство по п.1 или 2, отличающееся тем, что водные или водно-спиртовые растворы активированных - потенцированных форм антител к С-концевому фрагменту β-субъединицы рецептора инсулина и к эндотелиальной NO-синтазе получены путем многократного последовательного разведения в сочетании с внешним механическим воздействием - многократным встряхиванием каждого разведения из матричных растворов аффинно очищенных антител к С-концевому фрагменту β-субъединицы рецептора инсулина и к эндотелиальной NO-синтазе с концентрацией 0,5÷5,0 мг/мл.5. The drug according to claim 1 or 2, characterized in that aqueous or aqueous-alcoholic solutions of activated - potentiated forms of antibodies to the C-terminal fragment of the β-subunit of the insulin receptor and to endothelial NO synthase are obtained by repeated serial dilution in combination with external mechanical action - multiple shaking of each dilution from matrix solutions of affinity purified antibodies to the C-terminal fragment of the β-subunit of the insulin receptor and to endothelial NO synthase with a concentration of 0.5 ÷ 5.0 mg / ml 6. Лекарственное средство по п.1 или 2, отличающееся тем, что каждый из компонентов используют в виде смеси различных, преимущественно сотенных, разведении, приготовленных по гомеопатической технологии.6. The drug according to claim 1 or 2, characterized in that each of the components is used in the form of a mixture of various, mainly hundred, dilutions prepared according to homeopathic technology. 7. Лекарственное средство по п.4, характеризующееся тем, что фармацевтически приемлемые добавки включают изомальт, кросповидон и магния стеарат.7. The drug according to claim 4, characterized in that the pharmaceutically acceptable additives include isomalt, crospovidone and magnesium stearate. 8. Способ уменьшения резистентности к инсулину, включающий введение в организм активированной - потенцированной формы антител к рецептору инсулина, отличающийся тем, что одновременно и сочетано вводят дополнительный - усиливающий компонент в виде активированной - потенцированной формы антител к эндотелиальной NO-синтазе.8. A method of reducing insulin resistance, comprising introducing into the body an activated - potentiated form of antibodies to an insulin receptor, characterized in that at the same time an additional - enhancing component is introduced in combination as an activated - potentiated form of antibodies to endothelial NO synthase. 9. Способ лечения сахарного диабета, включающий введение в организм активированной - потенцированной формы антител к рецептору инсулина, отличающийся тем, что одновременно и сочетано вводят дополнительный - усиливающий компонент в виде активированной - потенцированной формы антител к эндотелиальной NO-синтазе.9. A method of treating diabetes mellitus, comprising administering to the body an activated - potentiated form of antibodies to an insulin receptor, characterized in that at the same time an additional - enhancing component in the form of an activated - potentiated form of antibodies to endothelial NO synthase is combined. 10. Способ лечения по п.9, отличающийся тем, что для лечения сахарного диабета I типа в организм вводят активированную - потенцированную форму антител к рецептору инсулина, одновременно и сочетано с активированной - потенцированной формы антител к эндотелиальной NO-синтазе.10. The method of treatment according to claim 9, characterized in that for the treatment of type I diabetes mellitus, an activated - potentiated form of antibodies to the insulin receptor is administered into the body, simultaneously and combined with an activated - potentiated form of antibodies to endothelial NO synthase. 11. Способ лечения по п.9, отличающийся тем, что для лечения сахарного диабета II типа в организм вводят активированную - потенцированную форму антител к рецептору инсулина, одновременно и сочетано с активированной - потенцированной формы антител к эндотелиальной NO-синтазе.11. The treatment method according to claim 9, characterized in that for the treatment of type II diabetes mellitus, an activated - potentiated form of antibodies to the insulin receptor is introduced into the body, and at the same time combined with an activated - potentiated form of antibodies to endothelial NO synthase. 12. Способ по п.8 или 9, отличающийся тем, что активированную - потенцированную форму антител к рецептору инсулина, и активированную - потенцированную форму антител к эндотелиальной NO-синтазе используют в виде активированного - потенцированного водного или водно-спиртового раствора, активность которого обусловлена процессом многократного разведения матричного раствора соответствующих антител в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - многократным встряхиванием каждого разведения.12. The method according to claim 8 or 9, characterized in that the activated — potentiated form of antibodies to the insulin receptor, and the activated — potentiated form of antibodies to endothelial NO synthase are used in the form of an activated — potentiated aqueous or aqueous-alcoholic solution, the activity of which is due to the process of repeated dilution of the matrix solution of the corresponding antibodies in an aqueous or aqueous-alcoholic solvent in combination with an external mechanical action - multiple shaking of each dilution. 13. Способ по п.8 или 9, отличающийся тем, что в организм вводят фармацевтическую композицию в виде единого лекарственного препарата - одной лекарственной формы, содержащую активированную - потенцированную форму антител к β-субъединице рецептора инсулина и активированную - потенцированную форму антител к эндотелиальной NO-синтазе.13. The method according to claim 8 or 9, characterized in that the pharmaceutical composition is introduced into the body in the form of a single drug - one dosage form containing an activated - potentiated form of antibodies to the β-subunit of the insulin receptor and an activated - potentiated form of antibodies to endothelial NO synthase. 14. Способ по п.13, отличающийся тем, что в организм вводят фармацевтическую композицию в виде единого лекарственного препарата - одной лекарственной формы, содержащую активированную - потенцированную форму антител к С-концевому фрагменту β-субъединицы рецептора инсулина и активированную - потенцированную форму антител к эндотелиальной NO-синтазе.14. The method according to item 13, wherein the pharmaceutical composition is introduced into the body in the form of a single drug - one dosage form containing an activated - potentiated form of antibodies to the C-terminal fragment of the β-subunit of the insulin receptor β and an activated - potentiated form of antibodies to endothelial NO synthase. 15. Способ по п.8 или 9, отличающийся тем, что в организм вводят фармацевтическую композицию в виде единого лекарственного препарата - одной лекарственной формы, содержащую активированную - потенцированную форму антител к α-субъединице рецептора инсулина и активированную - потенцированную форму антител к эндотелиальной NO-синтазе.15. The method according to claim 8 or 9, characterized in that the pharmaceutical composition is introduced into the body in the form of a single drug - one dosage form containing an activated - potentiated form of antibodies to the α-subunit of the insulin receptor and an activated - potentiated form of antibodies to endothelial NO synthase. 16. Способ по п.8 или 9, отличающийся тем, что в организм вводят фармацевтическую композицию в виде единого лекарственного препарата - одной лекарственной формы, содержащую активированную - потенцированную форму антител к α-субъединице рецептора инсулина и активированную - потенцированную форму антител к β-субъединице рецептора инсулина в сочетании с активированной - потенцированной формой антител к эндотелиальной NO-синтазе.16. The method according to claim 8 or 9, characterized in that the pharmaceutical composition is introduced into the body in the form of a single drug - one dosage form containing an activated - potentiated form of antibodies to the α-subunit of the insulin receptor and an activated - potentiated form of antibodies to β- subunit of the insulin receptor in combination with an activated - potentiated form of antibodies to endothelial NO synthase. 17. Способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами, отличающийся тем, что в организм дополнительно вводят фармацевтическую композицию, содержащую активированную - потенцированную форму антител к рецептору инсулина, преимущественно, к С-концевому фрагменту β-субъединицы рецептора инсулина и активированную - потенцированную форму антител к эндотелиальной NO-синтазе.17. A method of treating diabetes mellitus with insulin and / or hypoglycemic drugs, characterized in that the pharmaceutical composition is additionally introduced into the body, containing an activated - potentiated form of antibodies to the insulin receptor, mainly, to the C-terminal fragment of the insulin receptor β-subunit and activated - potentiated form of antibodies to endothelial NO synthase. 18. Способ по п.17, отличающийся тем, что активированную - потенцированную форму антител к С-концевому фрагменту β-субъединицы рецептора инсулина и активированную - потенцированную форму антител к эндотелиальной NO-синтазе используют в виде активированного - потенцированного водного или водно-спиртового раствора каждого компонента, активность которого обусловлена процессом многократного разведения в водном или водно-спиртовом растворителе в сочетании с внешним механическим воздействием - многократным встряхиванием каждого разведения.18. The method according to 17, characterized in that the activated - potentiated form of antibodies to the C-terminal fragment of the β-subunit of the insulin receptor and the activated - potentiated form of antibodies to endothelial NO synthase are used in the form of an activated - potentiated aqueous or aqueous-alcoholic solution each component, the activity of which is due to the process of multiple dilutions in an aqueous or hydroalcoholic solvent in combination with an external mechanical action - multiple shaking of each dilution. 19. Способ лечения по п.17 или 18, отличающийся тем, что фармацевтическую композицию используют в виде единого лекарственного препарата - одной лекарственной формы, содержащей смесь различных разведений антител к С-концевому фрагменту β-субъединицы рецептора инсулина в сочетании со смесью различных разведении антител к эндотелиальной NO-синтазе, приготовленных по гомеопатической технологии.19. The treatment method according to 17 or 18, characterized in that the pharmaceutical composition is used as a single drug - one dosage form containing a mixture of different dilutions of antibodies to the C-terminal fragment of the β-subunit of the insulin receptor β-subunit in combination with a mixture of different dilutions of antibodies to endothelial NO synthase prepared according to homeopathic technology. 20. Способ снижения уровня глюкозы, включающий введение в организм активированной - потенцированной формы антител к рецептору инсулина, отличающееся тем, что одновременно и сочетано вводят дополнительный - усиливающий компонент в виде активированной - потенцированной формы антител к эндотелиальной NO-синтазе. 20. A method of lowering glucose levels, including introducing into the body an activated - potentiated form of antibodies to an insulin receptor, characterized in that at the same time an additional - enhancing component in the form of an activated - potentiated form of antibodies to endothelial NO synthase is combined.
RU2011127051/15A 2010-07-15 2011-07-01 Drug for reducing insulin resistance and for treating diabetes, method of reducing insulin resistance, method of treating diabetes and method of treating diabetes with insulin and/or hypoglycemic preparations RU2509572C2 (en)

Priority Applications (64)

Application Number Priority Date Filing Date Title
RU2011127051/15A RU2509572C2 (en) 2011-07-01 2011-07-01 Drug for reducing insulin resistance and for treating diabetes, method of reducing insulin resistance, method of treating diabetes and method of treating diabetes with insulin and/or hypoglycemic preparations
CN2011800454899A CN103118707A (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
MX2013000543A MX2013000543A (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract.
MYPI2013000225A MY160979A (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
CZ20130124A CZ2013124A3 (en) 2010-07-21 2011-07-15 Combined pharmaceutical composition and methods of treating diabetes and metabolic diseases
ES201390009A ES2445846R1 (en) 2010-07-21 2011-07-15 A pharmaceutical combination composition and its use to prepare a medicament for the treatment of type 1 diabetes and metabolic disorders
EA201300124A EA029847B1 (en) 2010-07-21 2011-07-15 Combination pharmaceutical composition and method of treating diabetes mellitus and associated metabolic disorders
PE2013000076A PE20130398A1 (en) 2010-07-15 2011-07-15 A METHOD TO INCREASE THE EFFECT OF AN ACTIVE ENHANCED FORM OF AN ANTIBODY
GB1302924.4A GB2496799B (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
PCT/IB2011/002350 WO2012007845A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
KR1020187032943A KR20180127515A (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
SG2013002324A SG187038A1 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EP11775838.3A EP2593140A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
CA2804966A CA2804966A1 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
PCT/IB2011/002177 WO2012010966A2 (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
DE112011102358T DE112011102358T5 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
SG2013004817A SG187578A1 (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
ES201390006A ES2440393R1 (en) 2010-07-15 2011-07-15 A METHOD FOR INCREASING THE EFFECT OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY
IT000627A ITTO20110627A1 (en) 2010-07-21 2011-07-15 PHARMACEUTICAL COMPOSITION OF COMBINATION AND METHODS TO TREAT DIABETES AND METABOLIC DISORDERS
EA201300126A EA030566B1 (en) 2010-07-15 2011-07-15 Method of increasing therapeutic effectiveness of an activated-potentiated form of an antibody to an endogenous biological molecule and pharmaceutical composition
EP11773314.7A EP2595658A2 (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
BR112013001299A BR112013001299A2 (en) 2010-07-21 2011-07-15 pharmaceutical compositions and their use and methods of treating diabetes and related diseases in a human patient
BR112013000840A BR112013000840A2 (en) 2010-07-15 2011-07-15 method for enhancing the effect of potentiated activated form of antibody to biological endogenous molecule, pharmaceutical composition and use of combination of endogenous biological molecule with potentiated activated form of antibody to endothelial synthase.
KR1020137004330A KR20130103486A (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
FR1156480A FR2962913A1 (en) 2010-07-21 2011-07-15 PHARMACEUTICAL ASSOCIATION COMPOSITION AND USE THEREOF IN METHODS FOR TREATING DIABETES AND METABOLIC DISORDERS
IT000639A ITTO20110639A1 (en) 2010-07-15 2011-07-15 METHOD TO INCREASE THE EFFECT OF AN ACTIVE-ENHANCED SHAPE OF AN ANTI-BODY
CZ20130105A CZ2013105A3 (en) 2010-07-15 2011-07-15 Method of increasing effect of antibody activated potentiated form
NZ606964A NZ606964A (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
AU2011278038A AU2011278038B2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
DE112011102396T DE112011102396T5 (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and method for the treatment of diabetes and metabolic disorders
JP2013519175A JP2013538186A (en) 2010-07-15 2011-07-15 Method for increasing the effect of activation-enhancing antibodies
KR1020137003861A KR20140014059A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EEP201300007A EE05761B1 (en) 2010-07-21 2011-07-15 A combined pharmaceutical composition for treatment of diabetes and metabolic disorders
EEP201300006A EE201300006A (en) 2010-07-15 2011-07-15 A pharmaceutical composition for enhancing the effect of an activated and potentiated form of an antibody
JP2013520235A JP2013533268A (en) 2010-07-21 2011-07-15 Combination pharmaceutical composition and method for treating diabetes and metabolic disorders
NZ606767A NZ606767A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
FR1156482A FR2962656A1 (en) 2010-07-15 2011-07-15 METHOD FOR INCREASING THE EFFECT OF AN ACTIVATED-POTENTIALIZED FORM OF ANTIBODY
AU2011281240A AU2011281240B2 (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
EP19213849.3A EP3693018A1 (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
SG10201505561TA SG10201505561TA (en) 2010-07-15 2011-07-15 A Method Of Increasing The Effect Of An Activated-Potentiated Form Of An Antibody
CA2805961A CA2805961A1 (en) 2010-07-21 2011-07-15 Pharmaceutical composition comprising homeopathically potentized antibodies to human insulin receptor and endothelial no synthase
GB1302649.7A GB2495884B (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
US13/135,901 US9308275B2 (en) 2010-07-15 2011-07-15 Method of increasing the effect of an activated-potentiated form of an antibody
US13/135,891 US8617555B2 (en) 2010-07-21 2011-07-15 Pharmaceutical compositions comprising activated-potentiated antibodies to human insulin receptor and endothelial nitric oxide (NO) synthase
SE1350212A SE1350212A1 (en) 2010-07-21 2011-07-15 Pharmaceutical combination composition and methods for treating diabetes and metabolic disorders
PE2013000114A PE20130815A1 (en) 2010-07-21 2011-07-15 A COMPOSITION OF PHARMACEUTICAL COMBINATION AND METHODS TO TREAT DIABETES AND METABOLIC DISORDERS
MX2013000804A MX2013000804A (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders.
GB1707872.6A GB2552405B (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
ARP110102578A AR082247A1 (en) 2010-07-15 2011-07-18 A METHOD FOR INCREASING THE EFFECTS OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY
ARP110102642A AR082312A1 (en) 2010-07-21 2011-07-21 A PHARMACEUTICAL COMBINATION COMPOSITION TO TREAT DIABETES AND METABOLIC DISORDERS
CL2013000099A CL2013000099A1 (en) 2010-07-15 2013-01-10 A method of increasing the effect of an potentiated active form of an antibody to an endogenous biological molecule, comprising the combination of the endogenous biological molecule with an enhanced active form of an endoltelial non-synthase antibody; composition that understands it.
CL2013000200A CL2013000200A1 (en) 2010-07-21 2013-01-21 A pharmaceutical combination composition comprising an enhanced active form of an antibody to the human insulin receptor and an enhanced active form of a non-endothelial synthase antibody; method to treat diabetes and metabolic disorders.
NO20130222A NO20130222A1 (en) 2010-07-15 2013-02-08 Process for increasing the effect of an activated-potentiated form of an antibody
DKPA201370079A DK201370079A (en) 2010-07-15 2013-02-14 A method of increasing the effect of an activated-potentiated form of an antibody
LT2013016A LT5988B (en) 2010-07-15 2013-02-14 A method of increasing the effect of an activated-potentiated form of an antibody
FI20135143A FI20135143L (en) 2010-07-15 2013-02-15 A method of increasing the potency of an activated potentiated form of an antibody
NO20130265A NO20130265A1 (en) 2010-07-21 2013-02-18 A pharmaceutical combination preparation and methods for the treatment of diabetes and metabolic disorders
LT2013018A LT5980B (en) 2010-07-21 2013-02-19 Pharmaceutical composition for treating diabetes and metabolic disorders
DKPA201370089A DK201370089A (en) 2010-07-21 2013-02-19 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
FI20135152A FI20135152L (en) 2010-07-21 2013-02-21 PHARMACEUTICAL COMBINATION COMPOSITION FOR METHODS OF TREATMENT OF DIABETES AND METABOLIC DISEASES
US15/060,202 US20160251448A1 (en) 2010-07-15 2016-03-03 Method of increasing the effect of an activated-potentiated form of an antibody
US15/060,157 US20160244531A1 (en) 2010-07-15 2016-03-03 Method of increasing the effect of an activated-potentiated form of an antibody
JP2016131729A JP2016222684A (en) 2010-07-21 2016-07-01 Combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
JP2016135750A JP2016216483A (en) 2010-07-15 2016-07-08 Method of increasing effect of activated-potentiated antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2011127051/15A RU2509572C2 (en) 2011-07-01 2011-07-01 Drug for reducing insulin resistance and for treating diabetes, method of reducing insulin resistance, method of treating diabetes and method of treating diabetes with insulin and/or hypoglycemic preparations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2013152871/15A Substitution RU2565401C2 (en) 2013-11-28 2013-11-28 Method of treating diabetes mellitus and combined medication

Publications (2)

Publication Number Publication Date
RU2011127051A true RU2011127051A (en) 2013-01-10
RU2509572C2 RU2509572C2 (en) 2014-03-20

Family

ID=48795254

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011127051/15A RU2509572C2 (en) 2010-07-15 2011-07-01 Drug for reducing insulin resistance and for treating diabetes, method of reducing insulin resistance, method of treating diabetes and method of treating diabetes with insulin and/or hypoglycemic preparations

Country Status (1)

Country Link
RU (1) RU2509572C2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2565401C2 (en) * 2013-11-28 2015-10-20 Олег Ильич Эпштейн Method of treating diabetes mellitus and combined medication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2317981C2 (en) * 2001-12-14 2008-02-27 Ново Нордиск А/С Compounds and their using for decreasing hormone-sensitive lipase activity
RU2199345C1 (en) * 2001-12-26 2003-02-27 Эпштейн Олег Ильич Medicinal agent and method of regulation of carbohydrate and lipid metabolism
CA2632568A1 (en) * 2005-12-07 2007-06-14 Alacrity Biosciences, Inc. Tetracyclines for treating ocular diseases and disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2565401C2 (en) * 2013-11-28 2015-10-20 Олег Ильич Эпштейн Method of treating diabetes mellitus and combined medication

Also Published As

Publication number Publication date
RU2509572C2 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
CN1234414C (en) Drugs for complications of diabetes and neuropathy and utilization thereof
AR081254A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AVE0010 AND INSULIN GLARGINE
JP2009539827A5 (en)
JP2019517542A5 (en)
JP2013533268A5 (en)
JP2017538705A5 (en)
CA2896308C (en) Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
RU2020140694A (en) Method for treating hyperglycemia
RU2011127051A (en) MEDICINAL PRODUCT FOR REDUCING RESISTANCE TO INSULIN AND FOR TREATING SUGAR DIABETES, METHOD FOR REDUCING RESISTANCE TO INSULIN, METHOD FOR TREATING SUGAR DIABETES AND METHOD FOR TREATING ISOMEPHELIUM IN SUCHEMIUM
RU2014128612A (en) MODIFIED PEPTIDES AND THEIR APPLICATION FOR TREATMENT OF AUTOIMMUNE DISEASES
RU2013152871A (en) DIABETES TREATMENT METHOD AND COMBINED MEDICINE
RU2011127059A (en) NEUROTROPIC MEDICINE AND METHOD OF TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS
RU2010130348A (en) MEDICINAL PRODUCT FOR REDUCING RESISTANCE TO INSULIN AND TREATING DIABETES MELLITUS AND METHOD FOR INCREASING THE EFFECTIVENESS OF TREATING DIABETES MELLITUS WITH INSULIN AND / OR HYPOGLYCEMIC DRUGS
RU2010133052A (en) INTEGRATED MEDICINE FOR TREATMENT OF VIRAL INFECTIONS AND METHOD OF TREATMENT OF VIRAL INFECTIONS
RU2011127058A (en) MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
RU2016145411A (en) The combination of brexpiprazole and nalmefene, and its use for the treatment of the syndrome of chemical dependence
CN103239444A (en) Dextroindobufen and clopidogrel compound drug composition
CN117338772B (en) Pharmaceutical composition and application thereof in preparation of drugs for preventing and/or treating major depressive disorder
RU2010130355A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS
RU2008103666A (en) METHOD FOR TREATING ACUTE ALLERGY AND DEVICE FOR DELIVERY OF MEDICINES
RU2011124809A (en) MEDICINE FOR TREATMENT OF PATHOLOGICAL SYNDROME AND METHOD FOR TREATING FUNCTIONAL INTESTINAL DISORDERS
RU2010131386A (en) MEDICINAL PRODUCT FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISORDERS, AND METHOD FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISEASES
RU2011127055A (en) MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL-BEHAVIORAL DEVELOPMENT DISORDERS AND METHOD OF TREATMENT OF NEUROLOGICAL-BEHAVIORAL DISORDERS OF DEVELOPMENT
RU2010129297A (en) MEDICINAL PRODUCT FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISORDERS, AND METHOD FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISEASES
RU2010133050A (en) INTEGRATED MEDICINE FOR TREATMENT OF BACTERIAL INFECTIONS AND METHOD OF TREATMENT OF BACTERIAL INFECTIONS